Skip to main content
OpenTrials
Completed

NCT Number: NCT05520840

Evaluation of Peripheral Blood Protein Biomarkers for Colorectal Cancer Screening

The aim of the study is to validate the value of value of peripheral blood protein biomarkers in colorectal cancer screening, and to identify new ones

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colorectal Cancer Colonic Diseases Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Rectal Diseases

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Clinique du Cèdre, Bois-Guillaume, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient aged 50 years or older referred for screening colonoscopy after a positive FIT test or for endoscopic resection of a previously identified suspicious colorectal lesion

Exclusion criteria

  • Very high risk of colorectal cancer: Lynch syndrome, Familial adenomatous polyposis, Peutz-Jeghers syndrome, Familial polyposis associated with a MutYH gene defect
  • Other solid cancers or haematological malignancies that are progressive and/or undergoing treatment (apart from basal cell skin carcinoma)
  • Contraindication to total colonoscopy

Treatment and study plan

blood sampling for screening of biomarkers

Diagnostic Test

Patient aged 50 years or older referred for screening colonoscopy after a positive fecal immunochemical test or for endoscopic resection of a previously identified suspicious colorectal lesion will have a blood sampling for biomarkers detection

Primary outcomes

  1. Number of patient with advanced neoplasia at colonoscopy

    Time frame: Day 1

  2. Number of patient with presence of best isolated serum biomarkers selected from different candidates

    Time frame: Day 1

Secondary outcomes

  1. Number of patient with presence of other isolated serum biomarkers selected from different candidates

    Time frame: Day 1

Sponsors and collaborators

Lead sponsor

University Hospital, Rouen

Other

Collaborators

  • OncoDiag
  • University Hospital, Caen

Registry information

Acronym: COLODIAG

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Aug 30, 2022
Registry last updated
Feb 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.